患者报告的病结果:一项案例研究探讨了它们的使用和影响
Simona Lattanzi1, Angela La Neve2
1Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona - Italy.
Global & regional health technology assessment
|May 8, 2024
概括
专家认为,患者报告结果 (PRO) 措施对于改善患者护理和治疗成功至关重要. 时间和资源等障碍存在,但PRO可以优化管理和医疗保健利用.
科学领域:
- 神经学 神经学
- 临床研究 临床研究
- 医疗保健服务研究 医疗服务研究
背景情况:
- 的治疗依赖于有效的患者评估.
- 患者报告结果 (PRO) 措施为患者体验和生活质量提供了洞察力.
- 了解有关PRO使用的专家观点对于优化治疗至关重要.
研究的目的:
- 收集专家关于利用患者报告结果 (PRO) 措施的见解.
- 探索PROs对管理和医疗保健资源利用的影响.
主要方法:
- 一项结构化调查对一家三级医院的两个病转诊单位的负责人进行了结构化调查.
- 数据收集涉及纸质问卷和面对面的采访.
- 使用了各种生活质量和症状评估尺度,包括QOLIE-31,GAD-7和SF-36.
主要成果:
- 专家们就PRO对患者和疾病管理以及治疗成功度衡量的有利影响达成共识.
- 治疗结果被认为与治疗疗效和耐受性一样重要.
- 实施PRO的主要障碍包括缺乏时间,人员和经济资源.
- 专业医疗人员有潜力减少访问和治疗,同时增加以患者为中心的护理和专业服务.
结论:
- 关于PROs在优化病护理中的作用存在统一的看法,尽管目前的数据收集实践存在差异.
- 标准化PRO使用被认为是有益的,增加人力资源被确定为成功实施的优先事项.
相关概念视频
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287
Antiepileptic Drugs: GABAergic Pathway Potentiators
387
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
387
Antiepileptic Drugs: Glutamate Antagonists
321
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
321
Electroconvulsive Therapy
36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36


